Treatment of acute hepatitis B with lamivudine vs. placebo: A prospective randomized multicenter trial
J Wiegand, H Wedemeyer, A Franke, U Stölzel, S Zeuzem, G Teuber, M Wächtler, U Römmele, B Ruf, U Spengler, C Trautwein, J Thiery, MP Manns, O Brosteanu, HL Tillmann · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Acute hepatitis B virus infection can lead to fulminant liver failure with the consequence of liver transplantation or death. Several case series have attributed lamivudine with improved survival, prohibiting a placebo-controlled trial in fulminant hepatitis B. Even non-fulminant but severe acute hepatitis B (aHB) can lead to significant morbidity and impaired quality of life for a long period of time. We evaluated lamivudine in patients with severe acute hepatitis B in a placebo controlled trial. Methods: 40 Patients with severe aHB (>18 years, ALT >10x ULN, bilirubin >85µmol/l, prothrombin time >50%) wer…
